Edesa Biotech (RBTQ) Drug Pipeline
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Edesa Biotech (DE:RBTQ) have in its pipeline
Edesa Biotech DE:RBTQ is currently developing the following drugs: Eb06, Cohort A: Vilobelimab, Cohort B: Paridiprubart, Cohort C: Bevacizumab, Cohort A: Vilobelimab, Cohort C: Bevacizumab, Cohort B: Paridiprubart, Soc Plus 15Mg/Kg Eb05 Iv, Eb01 Cream 0.2%, Eb01 Cream 1.0%, Eb01 Cream 2.0%. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
